Related Experiment Videos
Complications and conversions in myeloproliferative disorders: an analysis of 356 cases
Yi Wang1, Anlan Zuo, Yinghui Liu
1Institute of Hematology, CAMS and PUMC, Tianjin 300020, China.
Objective:
To investigate the complications and conversions in myeloproliferative disorders (MPD).
Methods:
Three hundred and fifty six patients with MPD were reviewed, including 78 with etiologic thrombocythemia (ET), 93 with primary myelofibrosis (MF), 185 with polythythemia vera (PV). The clinical observation, follow-up, analysis with SPSS statistic software were performed.
Results:
Out of the 356 cases, 101 (28.5%) developed thromboembolic events, 81 (22.8%) hemorrhage, 60 (16.9%) hypertension, 20 (5.6%) coronary heart disease, 3 (0.8%) hemolysis and 1 (0.3%) gastrointestinal ulcer, 2 (0.6%) calculus and 1 (0.3%) bone marrow necrosis. Twenty four patients (6.7%) developed MF (9 in ET, 15 in PV), 2 (0.6%) erythrocytosis (1 in ET, 1 in MF), 3 (0.8%) thrombocythemia (all in PV), 5 (1.4%) acute leukemia (2 in ET, 3 in MF) and 1 (0.3%) multiple myeloma (in ET). Eleven cases (3.1%) died, 5 (1.4%) from acute leukemia, 2 (0.6%) fatal hemorrhages, 1 (0.3%) each myocardial infarction and infectious shock, 2 (0.6%) unknown causes.
Conclusion:
Embolism and bleeding were the main complications in MPD. Conversions among ET, MF and PV hematological malignancies could occur.
Insights
Complications like embolism and bleeding are common in myeloproliferative disorders (MPD). This study also found that these blood cancers can transform between essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV) subtypes.
Area of Science:
- Hematology
- Oncology
Background:
- Myeloproliferative disorders (MPD) are a group of chronic blood cancers.
- Understanding complications and disease progression is crucial for patient management.
Purpose of the Study:
- To investigate the spectrum of complications and potential conversions among different subtypes of myeloproliferative disorders.
- To analyze the incidence of thromboembolic events, hemorrhage, and malignant transformations.
Main Methods:
- Retrospective review of 356 patients diagnosed with MPD.
- Classified patients into essential thrombocythemia (ET), primary myelofibrosis (MF), and polycythemia vera (PV).
- Clinical data, follow-up information, and statistical analysis using SPSS software were employed.
Main Results:
- Thromboembolic events (28.5%) and hemorrhage (22.8%) were the most frequent complications.
- Other observed complications included hypertension (16.9%) and coronary heart disease (5.6%).
- Disease conversions were noted, with 6.7% developing myelofibrosis, and 1.4% progressing to acute leukemia.
Conclusions:
- Thromboembolism and bleeding represent significant complications in MPD.
- The study confirms that conversions between ET, MF, and PV subtypes can occur, highlighting the dynamic nature of these hematological malignancies.